Blog and news

Press Release | 23.03.2023

FDA Expands Indications for Use of FibroScan^® for Comprehensive Liver Management

Webinar | 16.03.2023

Leveraging FibroScan^® Solutions in Clinical Trials

Webinar | 10.03.2023

FibroScan^® Included in Key International Guidelines

Press Release | 13.02.2023

New AASLD Practice Guidance Calls for the Use of Noninvasive Liver Evaluations for Earlier Detection of NAFLD and NASH

Article | 02.11.2022

Addressing Link Between Obesity and Non-Alcoholic Fatty Liver Disease: New SmartExam Technology Extends Use of FibroScan^® Among Severely Obese Patients

Webinar | 02.11.2022

Unlocking the Clinical and Economic Value of FibroScan^®: Strategies for Optimizing Utilization and Reimbursement in Practice

Webinar | 02.11.2022

Understanding New FibroScan^® Software Enhancements Which Optimize Overweight Patient Testing

Article | 18.10.2022

Echosens Urges Increased Screening, Detection and Monitoring of Liver Health during October Liver Cancer Awareness Month

Article | 17.08.2022

Upcoming National Health Center Week Showcases Leaders in Preventative Medicine and Early Detection

Article | 26.07.2022

Halting Hepatitis: One of the World’s Major Public Health Crises

Webinar | 01.07.2022

FibroScan® Solutions Bringing New Guidelines to Life

Press Release | 23.06.2022

Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASH

Article | 22.06.2022

Rate of Body Mass Index Increase Doubled Among Pediatric Patients During COVID-19 Pandemic

Webinar | 15.06.2022

NIT-Based NAFLD Identification –
Understanding the New AGA Clinical Care Pathway

Article | 31.05.2022

FDA Expands Indications for Use of FibroScan® for Comprehensive Liver Management

Leveraging ​​​FibroScan® Solutions in Clinical Trials

FibroScan® Included in Key International Guidelines